CL2014003421A1 - Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. - Google Patents

Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.

Info

Publication number: CL2014003421A1
Authority: CL; Chile
Prior art keywords: glusose; gip; obesity; pharmaceutical composition; treatment
Prior art date: 2012-06-21

Application number

CL2014003421A

Other languages

English (en)

Inventor

Eric A Kitas

Richard D Dimarchi

David L Smiley

Konrad H Bleicher

Original Assignee

Univ Indiana Res & Tech Corp

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-21

Filing date

2014-12-17

Publication date

2015-05-22

2014-12-17 Application filed by Univ Indiana Res & Tech Corp, Hoffmann La Roche filed Critical Univ Indiana Res & Tech Corp

2015-05-22 Publication of CL2014003421A1 publication Critical patent/CL2014003421A1/es

Links

208000008589 Obesity Diseases 0.000 title 1
239000000556 agonist Substances 0.000 title 1
230000001419 dependent effect Effects 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000001747 exhibiting effect Effects 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
230000002473 insulinotropic effect Effects 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1
102000014187 peptide receptors Human genes 0.000 title 1
108010011903 peptide receptors Proteins 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000004584 weight gain Effects 0.000 title 1
235000019786 weight gain Nutrition 0.000 title 1
230000004580 weight loss Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2014003421A 2012-06-21 2014-12-17 Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. CL2014003421A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261662874P	2012-06-21	2012-06-21
US201361787973P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
CL2014003421A1 true CL2014003421A1 (es)	2015-05-22

Family

ID=48692696

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014003421A CL2014003421A1 (es)	2012-06-21	2014-12-17	Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.

Country Status (30)

Country	Link
US (2)	US9868772B2 (es)
EP (1)	EP2864350B1 (es)
JP (1)	JP6300239B2 (es)
KR (1)	KR20150039748A (es)
CN (1)	CN104583233B (es)
AR (1)	AR091478A1 (es)
AU (1)	AU2013277372B2 (es)
BR (1)	BR112014031671A2 (es)
CA (1)	CA2877127A1 (es)
CL (1)	CL2014003421A1 (es)
CO (1)	CO7170125A2 (es)
CR (1)	CR20150015A (es)
DK (1)	DK2864350T3 (es)
EA (1)	EA029025B1 (es)
ES (1)	ES2674946T3 (es)
HR (1)	HRP20180936T1 (es)
HU (1)	HUE039267T2 (es)
IL (1)	IL236386B (es)
MX (1)	MX356000B (es)
MY (1)	MY185217A (es)
PE (1)	PE20150863A1 (es)
PH (1)	PH12014502857A1 (es)
PL (1)	PL2864350T3 (es)
PT (1)	PT2864350T (es)
RS (1)	RS57347B1 (es)
SG (1)	SG11201408491SA (es)
SI (1)	SI2864350T1 (es)
TR (1)	TR201808818T4 (es)
TW (1)	TWI644920B (es)
WO (1)	WO2013192130A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2841437T (lt)	2012-04-26	2017-09-11	Bristol-Myers Squibb Company	Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
HRP20180936T1 (hr) *	2012-06-21	2018-12-14	Indiana University Research And Technology Corporation	Analozi glukagona koji pokazuju aktivnost prema receptoru za gip
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
LT3004155T (lt)	2013-05-28	2021-12-27	Takeda Pharmaceutical Company Limited	Peptidų junginys
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015095684A1 (en) *	2013-12-20	2015-06-25	Indiana University Research And Technology Corporation	Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
TW201625669A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CR20170164A (es)	2014-10-24	2017-08-29	Merck Sharp & Dohme	Coagonistas de los receptores de glucagón y de glp-1
MY185334A (en)	2014-12-30	2021-05-06	Hanmi Pharm Ind Co Ltd	Glucagon derivatives with improved stability
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EA201890058A1 (ru)	2015-06-30	2018-07-31	Ханми Фарм. Ко., Лтд.	Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh)	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
CN108697768B (zh)	2015-12-23	2022-07-22	约翰霍普金斯大学	长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
WO2017116204A1 (ko) *	2015-12-31	2017-07-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
WO2017204219A1 (ja)	2016-05-24	2017-11-30	武田薬品工業株式会社	ペプチド化合物
KR102005457B1 (ko)	2016-06-29	2019-07-30	한미약품 주식회사	글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
TW201833131A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110300A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
JOP20190211A1 (ar)	2017-03-31	2019-09-15	Takeda Pharmaceuticals Co	ببتيد منشط لمستقبل gip
CN120887972A (zh) *	2017-11-24	2025-11-04	浙江道尔生物科技有限公司	一种治疗代谢疾病的胰高血糖素类似物
EP3774838B9 (en)	2018-04-10	2025-12-10	Sanofi-Aventis Deutschland GmbH	Lixisenatide synthesis with capping
MX2020010716A (es)	2018-04-10	2021-03-09	Sanofi Aventis Deutschland	Metodo para escindir de la fase solida peptidos unidos a una fase solida.
KR102379958B1 (ko) *	2018-05-04	2022-04-01	노보 노르디스크 에이/에스	Gip 유도체 및 이의 용도
UY38249A (es)	2018-05-30	2019-12-31	Sanofi Sa	Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
CN112469731B (zh) *	2018-07-23	2024-11-29	伊莱利利公司	Gip/glp1共激动剂化合物
US11166910B2 (en)	2019-01-25	2021-11-09	Nordiccan A/S	Cannabinoid chewing gum with sugar alcohols
WO2021169512A1 (zh) *	2020-02-24	2021-09-02	中山大学	多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
AR121650A1 (es) *	2020-03-25	2022-06-22	Takeda Pharmaceuticals Co	Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
CN113493503B (zh) *	2020-04-08	2022-08-05	浙江道尔生物科技有限公司	一种肠促胰岛素类似物及其制备方法和用途
MX2023000303A (es)	2020-07-22	2023-02-09	Novo Nordisk As	Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
CN114621327B (zh) *	2020-12-10	2023-08-18	江苏中新医药有限公司	GLP-1、GIP和Gcg多重受体激动蛋白质
WO2022133797A1 (zh)	2020-12-23	2022-06-30	浙江道尔生物科技有限公司	一种长效胰高血糖素衍生物
WO2022156189A1 (zh) *	2021-01-22	2022-07-28	深圳市图微安创科技开发有限公司	多肽化合物在预防或治疗炎症性肠病及其相关的肠纤维化中的应用
EP4370537A4 (en) *	2021-07-16	2025-05-14	Pep2Tango Therapeutics Inc.	Compositions including multi-agonist peptides and methods of manufacture and use
TW202330584A (zh)	2022-01-20	2023-08-01	丹麥商諾佛儂迪克股份有限公司	前藥及其用途
CN115490760B (zh) *	2022-07-04	2023-04-14	北京惠之衡生物科技有限公司	一种glp-1受体和gcg受体共激动多肽衍生物
JP7402574B1 (ja) *	2023-03-15	2023-12-21	株式会社合同資源	α－ヨード置換カルボン酸

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4450150A (en)	1973-05-17	1984-05-22	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery depots, and method for preparing and using the same
AU597574B2 (en)	1986-03-07	1990-06-07	Massachusetts Institute Of Technology	Method for enhancing glycoprotein stability
IN165717B (es)	1986-08-07	1989-12-23	Battelle Memorial Institute
JP3266311B2 (ja)	1991-05-02	2002-03-18	生化学工業株式会社	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
EP1053752A1 (en)	1998-02-10	2000-11-22	Yoshitomi Pharmaceutical Industries, Ltd.	Preparations with controlled release
GB2344287A (en)	1998-12-03	2000-06-07	Ferring Bv	Controlled release pharmaceutical formulation
SE0302312D0 (sv) *	2002-10-04	2003-08-27	Forskarpatent I Syd Ab	Peptide-based passive immunization therapy for treatment of atherosclerosis
DE60331455D1 (de)	2002-10-04	2010-04-08	Microchips Inc	Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
JP2006524039A (ja)	2003-01-09	2006-10-26	マクロジェニクス，インコーポレーテッド	変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
US7846445B2 (en)	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US20080031957A1 (en)	2006-05-15	2008-02-07	Deluca Hector F	Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr)	2006-06-07	2008-09-05	Sapelem Soc Par Actions Simpli	Appareil de manutention de charge
AU2008216265B2 (en) *	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
NZ580700A (en)	2007-04-19	2012-01-12	Dong A Pharm Co Ltd	A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US8933197B2 (en)	2007-08-15	2015-01-13	Amunix Operating Inc.	Compositions comprising modified biologically active polypeptides
DK2300035T3 (en)	2008-06-17	2015-11-16	Univ Indiana Res & Tech Corp	Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (en) *	2008-06-17	2016-03-30	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
CN102325539A (zh)	2008-12-19	2012-01-18	印第安纳大学研究及科技有限公司	基于酰胺的胰高血糖素超家族肽前药
WO2010148089A1 (en) *	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
EP2528618A4 (en)	2010-01-27	2015-05-27	Univ Indiana Res & Tech Corp	GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
CA2797095A1 (en) *	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
RU2580317C2 (ru) *	2010-06-24	2016-04-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
BR112013032717A2 (pt) *	2011-06-22	2017-01-24	Univ Indiana Res & Tech Corp	coagonistas do receptor de glucagon/glp-1
RS56173B1 (sr) *	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
HRP20180936T1 (hr) *	2012-06-21	2018-12-14	Indiana University Research And Technology Corporation	Analozi glukagona koji pokazuju aktivnost prema receptoru za gip
ES2822994T3 (es) *	2014-09-24	2021-05-05	Univ Indiana Res & Tech Corp	Conjugados de incretina-insulina

2013
- 2013-06-18 HR HRP20180936TT patent/HRP20180936T1/hr unknown
- 2013-06-18 US US14/408,813 patent/US9868772B2/en not_active Expired - Fee Related
- 2013-06-18 SG SG11201408491SA patent/SG11201408491SA/en unknown
- 2013-06-18 AU AU2013277372A patent/AU2013277372B2/en not_active Ceased
- 2013-06-18 MX MX2014015556A patent/MX356000B/es active IP Right Grant
- 2013-06-18 EP EP13731246.8A patent/EP2864350B1/en not_active Not-in-force
- 2013-06-18 TR TR2018/08818T patent/TR201808818T4/tr unknown
- 2013-06-18 TW TW102121585A patent/TWI644920B/zh not_active IP Right Cessation
- 2013-06-18 PL PL13731246T patent/PL2864350T3/pl unknown
- 2013-06-18 JP JP2015518506A patent/JP6300239B2/ja not_active Expired - Fee Related
- 2013-06-18 RS RS20180728A patent/RS57347B1/sr unknown
- 2013-06-18 PE PE2014002465A patent/PE20150863A1/es not_active Application Discontinuation
- 2013-06-18 DK DK13731246.8T patent/DK2864350T3/en active
- 2013-06-18 ES ES13731246.8T patent/ES2674946T3/es active Active
- 2013-06-18 SI SI201331079T patent/SI2864350T1/en unknown
- 2013-06-18 CN CN201380043984.5A patent/CN104583233B/zh not_active Expired - Fee Related
- 2013-06-18 EA EA201590065A patent/EA029025B1/ru not_active IP Right Cessation
- 2013-06-18 PT PT137312468T patent/PT2864350T/pt unknown
- 2013-06-18 AR ARP130102143 patent/AR091478A1/es unknown
- 2013-06-18 HU HUE13731246A patent/HUE039267T2/hu unknown
- 2013-06-18 CA CA2877127A patent/CA2877127A1/en not_active Abandoned
- 2013-06-18 WO PCT/US2013/046229 patent/WO2013192130A1/en not_active Ceased
- 2013-06-18 KR KR20157001447A patent/KR20150039748A/ko not_active Abandoned
- 2013-06-18 BR BR112014031671A patent/BR112014031671A2/pt not_active Application Discontinuation
- 2013-06-18 MY MYPI2014003510A patent/MY185217A/en unknown
2014
- 2014-12-17 CL CL2014003421A patent/CL2014003421A1/es unknown
- 2014-12-21 IL IL236386A patent/IL236386B/en active IP Right Grant
- 2014-12-22 PH PH12014502857A patent/PH12014502857A1/en unknown
2015
- 2015-01-19 CR CR20150015A patent/CR20150015A/es not_active Application Discontinuation
- 2015-01-19 CO CO15009514A patent/CO7170125A2/es unknown
2017
- 2017-12-04 US US15/830,158 patent/US20180105569A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA201590065A1 (ru)	2015-07-30
KR20150039748A (ko)	2015-04-13
EP2864350A1 (en)	2015-04-29
EA029025B1 (ru)	2018-01-31
WO2013192130A1 (en)	2013-12-27
CR20150015A (es)	2015-04-24
TW201402603A (zh)	2014-01-16
CA2877127A1 (en)	2013-12-27
JP6300239B2 (ja)	2018-03-28
HRP20180936T1 (hr)	2018-12-14
MX2014015556A (es)	2015-03-05
US9868772B2 (en)	2018-01-16
CN104583233B (zh)	2018-10-23
PH12014502857A1 (en)	2015-02-23
US20150368310A1 (en)	2015-12-24
AU2013277372A1 (en)	2014-12-11
CO7170125A2 (es)	2015-01-28
MY185217A (en)	2021-04-30
PT2864350T (pt)	2018-05-14
MX356000B (es)	2018-05-08
AU2013277372B2 (en)	2018-03-29
TR201808818T4 (tr)	2018-07-23
EP2864350B1 (en)	2018-03-28
ES2674946T3 (es)	2018-07-05
SG11201408491SA (en)	2015-01-29
CN104583233A (zh)	2015-04-29
IL236386B (en)	2019-09-26
HUE039267T2 (hu)	2018-12-28
DK2864350T3 (en)	2018-05-28
PE20150863A1 (es)	2015-06-11
JP2015528795A (ja)	2015-10-01
AR091478A1 (es)	2015-02-04
TWI644920B (zh)	2018-12-21
SI2864350T1 (en)	2018-08-31
RS57347B1 (sr)	2018-08-31
BR112014031671A2 (pt)	2018-08-07
US20180105569A1 (en)	2018-04-19
PL2864350T3 (pl)	2019-01-31
IL236386A0 (en)	2015-02-26

Publication	Publication Date	Title
CL2014003421A1 (es)	2015-05-22	Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
CL2013002053A1 (es)	2013-11-29	Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CO7400885A2 (es)	2015-09-30	Análogos de glucagón
HUE039952T2 (hu)	2019-02-28	Glukagon/GLP-1 agonisták elhízás kezelésére
MX368435B (es)	2019-10-03	Analogos del glucagon.
PH12016500675B1 (en)	2016-05-30	Acylated glucagon analogues
CL2014002556A1 (es)	2015-02-13	Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
CL2014001994A1 (es)	2014-11-03	Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
AR092925A1 (es)	2015-05-06	Derivados de exendina-4 como agonistas duales de glp1 / glucagon
CL2013002414A1 (es)	2014-01-24	Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
ZA201507010B (en)	2017-08-30	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
ECSP12012351A (es)	2013-01-31	Análogos de glucagón
EP2718317A4 (en)	2015-04-08	GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
UY36779A (es)	2017-01-31	Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2015001699A1 (es)	2015-10-30	Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2012003722A1 (es)	2014-03-21	Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2014002845A1 (es)	2015-01-30	Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
UY32734A (es)	2010-11-30	Compuestos agonistas del receptor esfingosina 1-fosfato
CL2015001881A1 (es)	2015-11-06	Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2014003185A1 (es)	2015-04-24	Preformulacion de baja viscosidad que comprende pasireotida, agonista del receptor de somatostatina; proceso de preparacion de la preformulacion; kit farmaceutico; uso para tratar enfermedad de cushing o acromegalia.
CL2015000778A1 (es)	2015-08-21	Composición farmacéutica oral sinérgica que comprende nitazoxanida y mebendazol; proceso de preparación; y uso para el tratar parasitosis humana provocada por protozoos y helmintos.
IL241762B (en)	2020-03-31	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
ECSP15009978A (es)	2015-12-31	Análogos de glucagón